|Used to treat CD20 positive follicular non-Hodgkin's lymphoma. Has orphan drug designation by EMA for use to treat follicular lymphoma.
Unfortunately GlaxoSmithKline, the drug's manufacturer ceased production and sales of tositumomab in early 2014. The drug was clinically highly efficacious, but confounding market-driven factors lead to its commercial failure. Iinitial regulatory delays, manufacturing problems (on the radioactive component side), strong competition (new types of drugs for non-Hodgkin's lymphoma coming through the development pipeline, eg bendamustine), insufficient reimbursement by medical insurers and issues around physician referral patterns all influenced the decision to withdraw this drug from the market.